Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorFirst People's Hospital of Hangzhou

About this trial

This randomized controlled trial aims to evaluate the clinical efficacy of intradermal acupuncture as an adjunctive intervention to assist selective serotonin reuptake inhibitor (SSRI) dose reduction or discontinuation in adult patients with major depressive disorder (MDD). Participants receiving SSRIs and planning gradual dose reduction or discontinuation will be randomly assigned to one of three groups: SSRI tapering alone, sham intradermal acupuncture plus SSRI tapering, or intradermal acupuncture plus SSRI tapering. Clinical outcomes and autonomic nervous system function will be assessed to determine the effectiveness and potential mechanisms of intradermal acupuncture in facilitating SSRI reduction and alleviating withdrawal-related symptoms.

Eligibility criteria

Qualifiers

Adults aged 18-60 years

Disqualifiers

Severe uncontrolled primary medical conditions

Trial design

Treatments tested in this trial

  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Sham Intradermal Acupuncture
  • Intradermal Acupuncture

Treatment groups

114 Participants
are divided into 3 treatment groups

Locations

This trial has no locations